VEGFA and head and neck squamous cell carcinoma: This would lead to the hypothesis, that, according to our binary classification, a proportion of our HNSCC patients with <264 ng/L VEGFSerum could potentially be wrongly categorized as belonging to the “low VEGF—low risk group” and having superior outcomes, whereas VEGFPlasma > 26 ng/L correctly classifies them as belonging to the “high VEGF—high risk group”.